Preventative and therapeutic effects of perindopril on hepatic fibrosis induced by bile duct ligation in rats

Molecular Medicine Reports

Volumn 2, Issue 5, 2009, Pages 857-864

  Ueki, Masaru ^a   Koda, Masahiko ^a   Matono, Tomomitsu ^a   Sugihara, Takaaki ^a   Maeda, Kazunori ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Bile duct ligation; Hepatic stellate cells; Liver fibrosis; Oxidative stress; Perindopril

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; HYDROXYPROLINE; MESSENGER RNA; METALLOPROTEINASE; PERINDOPRIL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DISEASE COURSE; INTRAHEPATIC CHOLESTASIS; LIVER FIBROSIS; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; STELLATE CELL;

RATTUS;

EID: 69249214117     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000184     Document Type: Article

References (24)

1. Kagami S, Border WA, Miller DE and Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437, 1994. (Pubitemid 24177156)
2. Sun Y, Zhang J, Zhang JQ and Ramires FJ: Local angiotensin II and transforming growth factor-β1 in renal fibrosis of rats. Hypertension 35: 1078-1084, 2000. (Pubitemid 30327261)
3. Kupfahl C, Pink D, Friedrich K, et al: Angiotensin II directly increases transforming growth factor β1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc Res 46: 463-475 2000. (Pubitemid 30319332)
4. Molteni A, Moulder JE, Cohen EF, et al: Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 76: 523-532, 2000. (Pubitemid 30232452)
5. Bataller R, Gines P, Nicolas JM, et al: Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118: 1149-1156, 2000. (Pubitemid 30346992)
6. Yoshiji H, Kuriyama S, Yoshii J, et al: Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34: 745-750, 2001. (Pubitemid 32927999)
7. Ohishi T, Saito H, Tsusaka K, et al: Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol Res 21: 147-158, 2001. (Pubitemid 32899085)
8. Jonsson JR, Clouston AD, Ando Y, et al: Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121: 148-155, 2001. (Pubitemid 32591525)
9. Kurikawa N, Suga M, Kuroda S, Yamada K and Ishikawa H: An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 139: 1085-1094, 2003. (Pubitemid 36920670)
10. Tuncer I, Ozbek H, Ugras S and Bayram I: Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. Exp Toxic Pathol 55: 159-166, 2003.
11. Ueki M, Koda M, Yamamoto S, Matsunaga Y and Murawaki Y: Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol 41: 996-1004, 2006. (Pubitemid 44741413)
12. Terui Y, Saito T, Watanabe H, Togashi H and Kawata S: Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 36: 1022, 2002.
13. Ueki M, Koda M, Shimizu T, Mitsuta A, Yamamoto T and Murawaki Y: Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: A prospective study. Hepatogastroenterology (In Press).
14. Yokohama S, Yoneda M, Haneda M, et al: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40: 1222-1225, 2004. (Pubitemid 39425579)
15. Rimola A, Londono MC, Guevara G, et al: Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 78: 686-691, 2004. (Pubitemid 39244729)
16. Kountouras J, Billing BH and Scheuer PJ: Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 65: 305-311, 1984. (Pubitemid 14085298)
17. Yoshiji H, Kuriyama S, Kawata M, et al: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7: 1073-1078, 2001. (Pubitemid 32708747)
18. Murawaki Y and Hirayama C: Hepatic collagenolytic cathepsin in patients with chronic liver disease. Clin Chim Acta 108: 121-128, 1980. (Pubitemid 11225070)
19. Friedman SL: Liver fibrosis - from bench to bedside. J Hepatol 38: S38-S53, 2003.
20. Bataller R and Brenner DA: Liver fibrosis. J Clin Invest 115: 209-218, 2005.
21. Paizis G, Gilbert RE, Cooper ME, et al: Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrosis. J Hepatol 35: 376-385, 2001. (Pubitemid 32844192)
22. Bataller R, Schwabe RF, Choi YH, et al: NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112: 1383-1394, 2003. (Pubitemid 38057692)
23. Thiollet M, Funk-Brentano C, Grange JD, Midavaine M, Resplandy G and Jaillon P: The pharmacokinetics of perindopril in patients with liver cirrhosis Br J Clin Pharm 33: 326-328, 1992.
24. Komeda K, Jin D, Takai S, et al: Significance of chymase-dependent angiotensin II formation in the progression of human liver fibrosis. Hepatol Res 38: 501-510, 2008. (Pubitemid 351593951)